Acurx's DNA Pol IIIC Inhibitors Show Microbiome-Sparing Potential in MRSA Study

Event summary

  • Acurx presented preclinical data at ESCMID Global 2026 showing its DNA pol IIIC inhibitors preserve gut microbiome diversity while treating MRSA infections.
  • The study found Acurx's compounds maintained higher microbial diversity and prevented Proteobacteria expansion compared to linezolid.
  • Acurx's DNA pol IIIC inhibitors achieved therapeutic plasma levels and reduced MRSA tissue burden in neutropenic mice.
  • The findings suggest a class effect of microbiome preservation for DNA pol IIIC inhibitors, positioning them as potential additions to anti-Gram-positive therapeutic options.
  • Acurx received a new research grant from the Dutch government for further development of DNA pol IIIC inhibitors.

The big picture

Acurx's findings challenge the traditional trade-off between effective antibacterial activity and microbiome disruption, potentially offering a new paradigm in antibiotic development. The company's DNA pol IIIC inhibitors target Gram-positive infections classified as serious threats by the CDC, addressing a critical unmet need in the face of rising antibiotic resistance. With FDA QIDP and Fast-Track designations, Acurx is well-positioned to capitalize on regulatory incentives for novel antibiotic development.

What we're watching

Clinical Validation
Whether Acurx can translate these preclinical microbiome findings into clinical success for its DNA pol IIIC inhibitors.
Regulatory Pathway
The pace at which Acurx advances its ibezapolstat through Phase 3 trials for C. difficile infection and secures approvals.
Competitive Positioning
How Acurx's microbiome-sparing antibiotics differentiate in the market against existing treatments for Gram-positive infections.